Examining the evidence: A systematic review of the inclusion and analysis of older adults in randomized controlled trials

Journal of General Internal Medicine

Volumn 26, Issue 7, 2011, Pages 783-790

  Zulman, Donna M ^a,b,c   Sussman, Jeremy B ^a,b,c   Chen, Xisui ^a   Cigolle, Christine T ^b,d   Blaum, Caroline S ^b,d   Hayward, Rodney A ^a,b,c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

^d VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

Clinical trial methodology; Comorbidities; Exclusion criteria; Subgroup analysis

Indexed keywords

ADULT; AGE DETERMINATION; AGE DISTRIBUTION; AGE SPECIFIC CARE; CLINICAL TRIAL (TOPIC); COMORBIDITY; HEALTH STATUS; HUMAN; MEDLINE; METHODOLOGY; MORBIDITY; MORTALITY; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STUDY DESIGN; SYSTEMATIC REVIEW;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; COMORBIDITY; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 80051544511     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-010-1629-x     Document Type: Review

References (36)

1. Hartman M, Catlin A, Lassman D, Cylus J, Heffler S. US health spending by age, selected years through 2004. Health Aff (Millwood). 2008;27(1):w1-w12.
2. Machlin S. Trends in health care expenditures for the elderly age 65 and over: 2006 versus 1996. Statistical Brief #256. Rockville, MD. 2009.
3. McMurdo MET, Witham MD, Gillespie ND. Including older people in clinical research-benefits shown in trials in younger people may not apply to older people. Br Med J. 2005;331(7524):1036-7.
4. Besdine R, Boult C, Brangman S, et al. Caring for older Americans: the future of geriatric medicine. J Am Geriatr Soc. 2005;53(6 Suppl):S245-56.
5. The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010.
6. Thiemann DR, Coresh J, Schulman SP, Gerstenblith G, Oetgen WJ, Powe NR. Lack of benefit for intravenous thrombolysis in patients with myocardial infarction who are older than 75 years. Circulation. 2000;101(19):2239-46. (Pubitemid 30317124)
7. Scott IA, Guyatt GH. Cautionary tales in the interpretation of clinical studies involving older persons. Arch Intern Med. Apr 12;170(7):587-595.
8. Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS. Underrepresentation of patients 65 years of age or older in cancertreatment trials. N Engl J Med. 1999;341(27):2061-7. (Pubitemid 30035956)
9. Lewis JH, Kilgore ML, Goldman DP, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol. 2003;21 (7):1383-9. (Pubitemid 46606420)
10. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004;291(22):2720-6. (Pubitemid 38725421)
11. Lee PY, Alexander KP, Hammill BG, Pasquali SK, Peterson ED. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA. 2001;286(6):708-13.
12. O'Hare AM, Kaufman JS, Covinsky KE, Landefeld CS, McFarland LV, Larson EB. Current guidelines for using angiotensin-converting enzyme inhibitors and angiotensin II-receptor antagonists in chronic kidney disease: is the evidence base relevant to older adults? Ann Intern Med. 2009;150(10):717-24.
13. Cigolle CT, Blaum CS, Halter JB. Diabetes and cardiovascular disease prevention in older adults. Clin Geriatr Med. 2009;25(4):607-41. vii-viii.
14. Masoudi FA, Havranek EP, Wolfe P, et al. Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure. Am Heart J. 2003;146(2):250-7. (Pubitemid 36951768)
15. Humphreys K,Weingardt KR, Horst D, Joshi AA, Finney JW. Prevalence and predictors of research participant eligibility criteria in alcohol treatment outcome studies, 1970-98. Addiction. 2005;100(9):1249-57. (Pubitemid 41248066)
16. Agency for Healthcare Research and Quality. AHRQ Policy on the Inclusion of Priority Populations in Research: agency for healthcare research and quality, US Department of Health and Human Services. 2003.
17. US Government Accountability Office. Prescription drugs: FDA guidance and regulations related to data on elderly persons in clinical drug trials (GAO-07-47R). Washington, D.C.2007.
18. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22.
19. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264-9. W264.
20. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine-reporting of subgroup analyses in clinical trials. N Engl J Med. 2007;357(21):2189-94.
21. Rothwell PM. Treating Individuals 2-subgroup analysis in randomized controlled trials: importance, indications, and interpretation. Lancet. 2005;365(9454):176-86. (Pubitemid 40091809)
22. Altman DG, Schulz KF, Moher D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001;134(8):663-94. (Pubitemid 32322245)
23. Van Spall HGC, Toren A, Kiss A, Fowler RA. Eligibility criteria of randomized controlled trials published in high-impact general medical journals-a systematic sampling review. JAMA. 2007;297(11):1233-40. (Pubitemid 46465731)
24. Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med. 2002;21(19):2917-30.
25. Pocock SJ, Hughes MD, Lee RJ. Statistical problems in the reporting of clinical trials. A survey of three medical journals. N Engl J Med. 1987;317(7):426-32. (Pubitemid 17131180)
26. Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet. 2000;355 (9209):1064-9. (Pubitemid 30162810)
27. Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA. 1991;266(1):93-8.
28. Parker AB, Naylor CD. Subgroups, treatment effects, and baseline risks: some lessons from major cardiovascular trials. Am Heart J. 2000;139 (6):952-61. (Pubitemid 30390322)
29. Brookes ST, Whitely E, Egger M, Smith GD, Mulheran PA, Peters TJ. Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test. J Clin Epidemiol. 2004;57(3):229-36. (Pubitemid 38456874)
30. Hernandez AV, Boersma E, Murray GD, Habbema JDF, Steyerberg EW. Subgroup analyses in therapeutic cardiovascular clinical trials: are most of them misleading? Am Heart J. 2006;151(2):257-64. (Pubitemid 43148981)
31. Hayward RA, Kent DM, Vijan S, Hofer TP. Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis. BMC Med Res Methodol. 2006;6:18.
32. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001;357(9263):1191-4.
33. Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med. 2006;25 (1):127-41. (Pubitemid 43136953)
34. Sun X, Briel M, Walter SD, Guyatt GH. Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ. 340:c117.
35. Kent DM, Rothwell PM, Ioannidis JP, Altman DG, Hayward RA. Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials. 2010;11:85.
36. Rothwell PM, Mehta Z, Howard SC, Gutnikov SA, Warlow CP. Treating individuals 3: from subgroups to individuals: general principles and the example of carotid endarterectomy. Lancet. 2005;365:256-65. (Pubitemid 40138020)